Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Mucosa, Inflammation, Tissue Viral Load, Anti-inflammatory, HIV-related diarrhea, Mucosal Inflammation, Treatment Experienced
Eligibility Criteria
Inclusion Criteria HIV infected Stable plasma viral load between 500 and 100,000 copies/ml for 3 months prior to study entry Stable antiretroviral therapy for at least 3 months prior to study entry CD4 cell count greater than or equal to 200 cells/mm3 Mucosal viral RNA greater than or equal to 100 copies/microg total RNA within 2 weeks of study entry Exclusion Criteria Allergy or intolerance to salicylates Gastrointestinal tract infection causing diarrhea or colonic inflammation Renal or hepatic disease Current opportunistic infection History of extensive small bowel resection (greater than 1/2 the length of the small intestine) History of intestinal mucosal disease (except HIV) Chronic, regular use of aspirin and/or anti-inflammatory agents within 7 weeks prior to study entry Oral, topical, or rectal steroids or 5-ASA within 3 months prior to study entry Certain laboratory abnormalities Significant neuropsychiatric symptoms that in the opinion of the study official could impact the conduct or outcome of the study
Sites / Locations
- David Geffen School of Medicine at UCLA